Sr

Que
Interventions for severe tricuspid regurgitation.
Prognostic role of CT Coronary calcium score.
Calcified coronary artery disease: Pathophysiology, intracoronary imaging
assessment and calcified plaque modification techniques (with relative advantages
& disadvantages over each other) OR Devices used for calcium modification in
coronary artery disease or Coronary debulking strategies and devices: current status
MAPSE (Mitral Annular Plane Systolic Excursion): Methodology, clinical application
and limitations.
Distal myocardial preservation/protection during percutaneous coronary
intervention: when and how
Septal ablation techniques in patients with HOCM
Robotic PCI – Potential advantages and disadvantages
Transcatheter management of mitral regurgitation.
Recent advances in management of aortic stenosis
Discuss and compare the various intravascular imaging techniques in complex
coronary intervention and their role in outcomes.
Management of myocardial INFARCTION AFTER TX
Shifting burden and epidemiologic transitions: Five typical stages of epidemiological
transitions in CVD mortality and types.
Coronary artery disease epidemiology in India: current trends
Intravascular lithotripsy.
Current status of OCT.
Management of a patient presenting with acute STEMI taking oral anticoagulation
for chronic AF.
Microvascular angina.
Dual antiplatelet after coronary stent implantation - Current status.
SYNTAX II in real world.
Current status of FFR guided percutaneous coronary intervention (PCI) in a
angiographically borderline lesion during PCI.
Percutaneous
Describe hemodynamic
in detail assist
regarding the methods.
clinical applications and advances in physiological
assessment of coronary artery stenosis. OR Describe the Instant wave free ratio
(IFR)
Pharmaco-invasive approach to STEMI management.
Role of thrombosuction in primary PCI.
Interventional management of coronary bifurcation diseases.
Complications of rotablation and its management.
Assessment of myocardial viability
Perinatal and early childhood factors contributing to coronary artery disease risk.
Current status of - a) Bioreabsorbable stents b) IVC Filter c) Thrombus aspiration
during PAMI
How do you assess a patient of IHD with severe LV dysfunction for coronary
revascularization? b) Device occlusion of left atrial appendage – current status. c)
Clinical trials of fractional flow reserve.
Role of Optimal Coherence Tomography (OCT) in predicting vulnerable plagues. b)
What are the other modalities of intravascular imaging?
Present status of hybrid coronary revascularization
Deferred stenting.
Re entry devices for chronic total occlusions.
Preventive stenting in STEMI.
Drug eluting balloons
Role, method and current status of hybrid revascularization.
Repeat
Done
Brwn ch 20 pg 337 Done

II Csi-23/2 - ch 148 D

II
Brwn j
Done

II

Csi 2023/2 D

Csi

Csi 2023/2 D
Ffr ch D

III Brwn ch 36 pg 617

Csi 2023/2 D
Csi ncl in stemi D
Sr Que
Role of Telemedicine in current practice.
Name two drugs using the anti-inflammatory pathway in the management of
cardiac patients with at least one trial in support of the drugs
New and emerging therapies for lowering of LDL-cholesterol OR Current status
of PCSK-9 inhibitors OR Non statin management of dyslipidemia.
Recent advances in management of hyperlipidemias
Omecamtiv mecarbil.
Vericiguat.
Describe the indications and contraindications of SGLT-2 inhibitors in heart
failure. OR SGLT2 inhibitors in heart failure: current status.
Evidence based interventions to raise HDL cholesterol
Aspirin for primary prevention - current controversy
Management of statin intolerance.
Indian dyslipidemIA AND MX
Antidotes for DOACs. Or Factor Xa inhibitors b) RE-LY Trial c) Antidote for
newer oral anticoagulants.
Pharmacogenomics.
G protein coupled receptor(GPCR) activity for cardiovascular disease
Enumerate chemotherapeutic agents causing cardiotoxicity.
Statin associated myopathy – Clinical features and management.
What is the pharmacogenetic approach to warfarin therapy? What are the
advantages?
IIII

III

III
Discuss in brief Trans Aortic Valve Replacement (TAVR) in intermediate
surgical risk patients.
Valve-in-valve TAVR. b) Enumerate the various valves used in TAVR. c)
Recent clinical trials in TAVR.
Discuss current indications of Transcatheter Mitral Valve Edge to Edge
repair (Mitra Clip).

Sizing of percutaneous aortic valve

Trans catheter Aortic Valve Implantation compared to Surgical
Aortic Valve Replacement
Vascular access and its management in percutaneous aortic valve
implantation
Percutaneous approaches to mitral valve diseases. b) Percutaneous
approaches to aortic valve diseases. c) Percutaneous approaches to
pulmonary valve diseases.
Transmitral valve implantation: current status
Development of transcatheter mitral valve repair. b) MV repair studies in
heart failure.
Percutaneous pulmonary valve replacement: current status
Latest revision of Duckett Jones Criteria for diagnosis of Acute
Rheumatic Fever.
Denervation therapy in the treatment of cardiovascular diseases
Current indications of Trans Catheter Aortic Valve Replacement (TAVR).
Discuss current evidence of Left Atrial Appendage Closure for Stroke
prevention.
Device therapies for hypertension.
Atrial flow regulator.
Sizing of devices for ASD, VSD and PDA closure.
Acute & long term complications of VSD closure.
Management of post cardiac transplant patient.
Risk factors and classification of aortic dissection. b) Imaging for aortic
dissection c) Management of aortic dissection.
 Sts
Brwn as ch D criteria

Csi 2023/2 ch 190 D

II
Ppt ipad/ speed
2023/2 pg 1347 D Done
Speed/csi 2023/2 pg
II 1353 D

Csi 2023/2 D

Csi 2023/2 D

Brwn D

II Brwn D
Done
Sr Que
a) Artificial Intelligence in Cardiology.
Clinical cardiovascular manifestations of COVID-19 and the possible
mechanisms involved during and after covid 19 or COVID-19 and
cardiovascular disease: describe briefly various manifestations and treatment.
OR COVID-19 infection and coagulation abnormalities
Describe the clinical utility of Renal Denervation therapy in management of
Resistant Hypertension.
Discuss the Phases of valsalva maneuvre.
ECMO: indications and limitations
Artificial heart.
Secondary prevention of acute rheumatic fever OR Drug regimen of choice of
primary prevention and secondary prevention of rheumatic fever.
Exercise based comprehensive cardiac rehabilitation.
Diagnostic criteria for infective endocarditis.
Management outline of prosthetic valve or prosthetic material endocarditis.
Post Cardiac Injury Syndromes.
Cardiac involvement in HIV.
Evaluation of adult patient who has survived out of hospital cardiac arrest.
Cardiovascular complications of cocaine use.
Dallas criteria.
Evaluation of a potential heart transplant recipient. b) Ventricular Assist
Devices – current status
Current concepts in management of renovascular hypertension in adults. b)
Etiology and management of renovascular hypertension in India.
Principles of cell and gene based cardiac regenerative therapies b) Cell and
Gene delivery systems. c) Clinical trials of gene therapy.
Stem cell therapy in cardiac disorders
Describe therapeutic hypothermia and its role in cardiac arrest.
What is Bayes’ theorem? Discuss sensitivity and specificity of -exercise
electrocardiography in coronary artery disease.
II Done

IIIII

Done
Done
II CSI 2/23 CH 208 PG 1618 Done

II

Speed notes/2023 guidelinees Dr

Brwn D
Brwn Done

Speed D
Speckle Tracking echocardiography.
3D Echocardiography: Concept and clinical applications
Fallacies of measuring ejection during Echocardiography
Noninvasive FFR (Fractional Flow Reserve). b) Precautions while
performing FFR to ensure accuracy. c) Clinical trials indicating utility of
FFR.
Application of radio nuclide imaging in chest pain syndrome. b) Intra-
operative TEE – current status c) Enumerate catheter based treatment in
Tetralogy of Fallot.
Compare and contrast 3D echocardiography with TEE
applications
What are theofcurrent
real time 3D Echo.and status of Fetal Cardiac
indications
interventions?
Sr Que
COVID and PAH. (Who type 3 )
Percutaneous interventions in patients with PAH
Newer drugs used in the treatment of PAH OR Novel pharmacotherapies for
pulmonary arterial hypertension in 2021
Pathology, classification and cardiovascular manifestation of Takayasu arteritis
b) Kawasaki disease – clinical features, diagnosis and natural history.
Role of carotid artery revascularization in patients with coronary artery
disease. b) Recent clinical trials associated with carotid revascularization.
Catheter interventions in acute pulmonary embolism
 CSI 1/23 CH 119,120,121

IIIII CSI 1/23 CH 119,120,121

Brwn ch 97 D

Brwn
Sr Que
Leadless Pacemaker. [5] b) Subcutaneous ICD.
Describe recent advances in non-pharmacological management of Atrial
Fibrillation
Describe the selection of patient for Cardiac Resynchronisation Therapy (CRT)
and the clinical indicators of response to CRT.
Describe the Vaughan William classification of anti-arrhythmic drugs and thier
role in various stages of Action Potential.
Describe Idiopathic Fascicular Left Ventricular Tachycardia (ILVT) and its
management.
Discuss HIS bundle pacing and its advantages over conventional pacing.
Remote monitoring devices for arrhythmia: types, indications and Limitations.
Physiologic pacing strategies: Indications and technique.
Alternative sites for permanent pacing.
MRI conditional pacemaker.
AICD for non-ischemic cardiomyopathy: current status
Ablation of ventricular tachycardia in patients with structural heart disease. b)
What is MADIT-CRT long term follow up?
Wearable ICD - Design and indications.
Management of VT storm in the post ICD implant.
What are subcutaneous defibrillators? What are their advantages and
disadvantages
IIII CSI

II

SPEED NOTES

Hurst Dr
HURST ?

Brwn D

HURST/BRWN
Sr Que
A 28-year male, with history of cyanotic congenital heart disease diagnosed
at age of five years and underwent intracardiac repair, presented with
dyspnoea. On evaluation, he had pan diastolic murmur heard over left
parasternal border. The clinical findings were confirmed on echocardiography
and there was dilated RVOT and RV dysfunction. What is the clinical condition?
How do you manage the case percutaneously?
Palliative surgeries in Tetralogy of Fallot
Fontan operation: Complications and their treatment. OR Fontan surgery:
Indications and prerequisites.
Describe aorto-pulmonary collaterals in cyanotic heart diseases. Explain their
physiological and applied importance
Assessment of ASD size during percutaneous ASD closure
Enumerate various palliative surgical procedures in congenital heart. disease
treatment. Describe in brief at least 4 such procedures
Grown Ups with Congenital Heart(GUCH) disease.
Perinatal interventions in Duct Dependent Systemic and pulmonary
circulations.
Pre-requisites for a Fontan surgery
Natural history of Ostium Secundum ASD b) Assessment for device closure c)
How do you manage an adult patient (>40 years) with ASD and PAH.
II
Sr Que

a) ORBITA trial. Clinical implications. [5] b) AVATAR trial. Clinical implications.

[5]
Describe about the trial evidence regarding Aspirin in the primary prevention
of cardiovascular disease.
EROSION III trial
FLOWER-MI trial.
ISCHEMIA trial.
Recent trials of colchicine for coronary artery disease.
PARTNER 2 trial + PARTNER -3 trial.
LoDoCo2 study.
The TICO Trial.
DAPA-HF Trial.
CABANA Trial.
AUGUSTUS trial.
PIONEER-HF trial.
CULPRIT-SHOCK Trial.

Chicine negative trail

Ctca negative trail
Conclusions regarding cardiovascular risk factors in INTERHEART Study.
PARTNER Trial b) PARADIGM HF Trial c) COURAGE Trial
EXCEL Trial.
FREEDOM Trial: Describe inclusion criteria and results.

TRILUMINATE PIVOTAL
STRONG HF
TRANSFORM HF
VALOR HCM
INVICTUS
PACMAN-AMI
FLAVOR
EARLY HF
IRONMAN
BCIS
BIOVASC
ZILBESIRAN FOR HTN
CHRONIC HTN AND PREG
II

II Speed D

Colchicine

II

CSI UPDATE 1/24 - CH 130

CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
CSI UPDATE 1/24 - CH 130
Sr Que
Describe about the risk stratification in a patient with family history of SCD
and Hypertrophic cardiomyopathy.
Discuss in brief the newer modalities in management of heart faliure.
Implantable devices to monitor heart failure.
Reversible cardiomyopathies.
Management of hyponatremia in heart failure.
Extracorporeal ultrafiltration for fluid overload in heart failure. b) Current
drugs which are under development for treatment of heart failure.
Mechanical circulatory support in cardiogenic shock.
Alcohol ablation versus surgical myomectomy in hypertrophic obstructive
cardiomyopathy.
Role of Neprilysin inhibitor in heart failure and hypertension.
Left ventricular assist devices.
II Brwn/speed notes D

One note D
Sr Que
Define Resistant Hypertension and Refractory Hypertension. Describe about
recent advances in management of Resistant Hypertension and trial evidence
Types of prevention of heart disease. Illustrate with diagram and examples
Novel approaches to preventive cardiology: Polypill in current practice,
precision medicine vs preventive medicine.
Cardiovascular and metabolic effects of air pollution
Describe in brief two device based therapy for hypertension
Discuss briefly the primary prevention strategy for Atherosclerotic
Cardiovascular disease (ASCVD) and risk scoring systems for primary
prevention.
Interventions for smoking cessation.
HDL- Paradox.
Dietary modification in primary prevention of cardiovascular diseases.
Smoking and its cardiovascular effects.
Done
Done

Done
Done
Done

Done
Done
Done
Done
Done